24/7 Market News Snapshot 29 January, 2025 – Ocean Biomedical, Inc. Common Stock (NASDAQ:OCEA)

January 29, 2025

DENVER, Colo., 29 January, 2025 (247marketnews.com) – (NASDAQ:OCEA) are discussed in this article.
Ocean Biomedical, Inc. has experienced a significant surge in market performance, with shares climbing to $0.610, reflecting an impressive 84.85% increase from the previous close of $0.330 during the pre-market session. This dramatic rise, characterized by an elevated trading volume of 17.87 million shares, highlights a robust interest among investors and a favorable sentiment surrounding the company’s future prospects. Analysts are closely monitoring these developments as they may indicate the onset of a promising period for Ocean Biomedical.

Concurrently, Ocean Biomedical is advancing its pivotal research in malaria vaccine development, led by its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD. The team has recently secured additional funding from the National Institutes of Health (NIH), aimed at furthering their groundbreaking efforts in addressing global health challenges posed by malaria. Traditionally, progress in malaria vaccine development has been hampered by ineffective target selection strategies. In a novel approach, Dr. Kurtis’s research has pivoted towards understanding the immune responses of children exhibiting natural resistance to the disease. This has led to the identification of the glutamic acid-rich protein (GARP) on malaria-infected red blood cells, which has emerged as a promising target for vaccine candidates.

The research team is now testing three vaccine candidates in non-human primates, designed to block the malaria parasite’s entry into and exit from red blood cells. With recent FDA guidance on lipid-encapsulated vaccines, the transition to clinical trials could commence as early as the fourth quarter of 2025, a timeline that has generated excitement among stakeholders.

In addition to the NIH funding, Dr. Kurtis has received a grant of $3.5 million to refine optimal vaccine targets to protect children from malaria. Expressing enthusiasm for the project’s trajectory, Dr. Kurtis remarked on the transformative potential of the emerging data, while Ocean Biomedical’s Chairman, Dr. Chirinjeev Kathuria, underscored the validation of their innovative technology in the fight against malaria. Ocean Biomedical remains steadfast in its commitment to delivering impactful solutions to significant health challenges.

Related news for (OCEA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.